Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED)

[摘要] Background: In 2015, Vyvanse (lisdexamfetamine) became the first Food and Drug Administration (FDA)-approved treatment for binge-eating disorder (BED), a condition first recognized by the DSM–V in 2013. Because pharmaceutical companies use continuing medical education (CME) to help sell drugs, we explored possible bias in CME modules on BED.

[学科分类] 过敏症与临床免疫学

[关键词] Amphetamines;Binge-Eating Disorder;Continuing Medical Education;Lisdexamfetamine;Quality of Life;Weight Loss